학술논문
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Document Type
Article
Author
Source
In European Urology Oncology September 2019 2(5):565-571
Subject
Language
ISSN
2588-9311